Concepedia

Matthias Treu

MT

Statistics

Publications

14

Citations

564

H-Index

12

Active since

2001

Affiliations

Boehringer Ingelheim (Austria)(Current)

Boehringer Ingelheim (Germany)

TU Wien

The University of Texas MD Anderson Cancer Center

Vanderbilt University

Matthias Treu is an author at Boehringer Ingelheim (Austria) specializing in pharmacology, medicine, and drug discovery.

Top concepts

Publications per year

2001–2024

14

Publications

14

Tumor cell‐specific inhibition of <scp>MYC</scp> function using small molecule inhibitors of the <scp>HUWE</scp> 1 ubiquitin ligase

Stefanie Peter, Jennyfer Bultinck, Kevin Myant et al. · EMBO Molecular Medicine · 2014 · 119 citations · Full text

Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine Biosynthesis

Harald Weinstabl, Matthias Treu, Joerg Rinnenthal et al. · Journal of Medicinal Chemistry · 2019 · 80 citations · Full text

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS <sup>G12C</sup> Inhibitor

Joachim Bröker, Alex G. Waterson, Chris A. Smethurst et al. · Journal of Medicinal Chemistry · 2022 · 72 citations · Full text

Microwave-Assisted Parallel Synthesis of Fused Heterocycles in a Novel Parallel Multimode Reactor

Matthias Treu, Thomas Karner, Roland Kousek et al. · Journal of Combinatorial Chemistry · 2008 · 52 citations

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Birgit Wilding, Dirk Scharn, Dietrich Böse et al. · Nature Cancer · 2022 · 44 citations

, , +10

1–5 of 14